TCR2 Therapeutics Inc. is a clinical-stage cell therapy company developing a pipeline of novel T cell therapies for patients suffering from solid tumors or hematological malignancies. TCR2's proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC®-T cells) specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA). In preclinical studies, TRuC-T cells have demonstrated superior anti-tumor activity compared to chimeric antigen receptor T cells (CAR-T cells), while secreting lower levels of cytokine release. The Company's lead TRuC-T cell product candidate targeting solid tumors, gavo-cel, is currently being studied in a Phase 1/2 clinical trial to treat patients with mesothelin-positive non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. The Company's lead TRuC-T cell product candidate targeting hematological malignancies, TC-110, is currently being studied in a Phase 1/2 clinical trial to treat patients with CD19-positive adult acute lymphoblastic leukemia (aALL) and with aggressive or indolent non-Hodgkin lymphoma (NHL).
Company profile
Ticker
TCRR
Exchange
Website
CEO
Garry Menzel
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
474152751
TCRR stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
12 Jun 23
EFFECT
Notice of effectiveness
6 Jun 23
EFFECT
Notice of effectiveness
6 Jun 23
EFFECT
Notice of effectiveness
6 Jun 23
POS AM
Prospectus update (post-effective amendment)
1 Jun 23
POS AM
Prospectus update (post-effective amendment)
1 Jun 23
POS AM
Prospectus update (post-effective amendment)
1 Jun 23
S-8 POS
Registration of securities for employees (post-effective amendment)
1 Jun 23
S-8 POS
Registration of securities for employees (post-effective amendment)
1 Jun 23
S-8 POS
Registration of securities for employees (post-effective amendment)
1 Jun 23
Transcripts
Latest ownership filings
4
KEVIN C TANG
14 Feb 24
SC 13G/A
TANG CAPITAL PARTNERS LP
14 Feb 24
4
Change in insider ownership
5 Jun 23
4
Change in insider ownership
5 Jun 23
4
LUKE EVNIN
5 Jun 23
4
ANSBERT GADICKE
5 Jun 23
4
Andrew R Allen
1 Jun 23
4
Shawn Tomasello
1 Jun 23
4
Eric Sullivan
1 Jun 23
4
Alfonso Quintas Cardama
1 Jun 23
Financial summary
Quarter (USD) | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 15.60 mm | 15.60 mm | 15.60 mm | 15.60 mm | 15.60 mm | 15.60 mm |
Cash burn (monthly) | 6.10 mm | 4.97 mm | 13.84 mm | 13.82 mm | 13.34 mm | 9.19 mm |
Cash used (since last report) | 78.45 mm | 63.95 mm | 177.93 mm | 177.69 mm | 171.51 mm | 118.25 mm |
Cash remaining | -62.85 mm | -48.36 mm | -162.33 mm | -162.09 mm | -155.91 mm | -102.65 mm |
Runway (months of cash) | -10.3 | -9.7 | -11.7 | -11.7 | -11.7 | -11.2 |
Institutional ownership, Q1 2023
63.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 58 |
Opened positions | 7 |
Closed positions | 14 |
Increased positions | 12 |
Reduced positions | 16 |
13F shares | Current |
---|---|
Total value | 28.14 bn |
Total shares | 24.96 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
MPM Asset Management | 4.05 mm | $6.08 bn |
Tang Capital Management | 3.40 mm | $5.10 bn |
MPM Oncology Impact Management | 3.37 mm | $5.06 bn |
Tang Capital Partners | 2.74 mm | $0.00 |
Vanguard | 1.47 mm | $2.20 bn |
Upnorth Investment | 1.28 mm | $39.63 mm |
Newtyn Management | 1.02 mm | $1.52 bn |
Acadian Asset Management | 812.46 k | $1.22 mm |
BLK Blackrock | 789.91 k | $1.18 bn |
Baker Bros. Advisors | 753.06 k | $1.13 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Jun 23 | Gibson Neil W | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 6.07 | 8,072 | 49.00 k | 0 |
1 Jun 23 | Gibson Neil W | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 5.21 | 12,100 | 63.04 k | 0 |
1 Jun 23 | Gibson Neil W | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 31.83 | 12,100 | 385.14 k | 0 |
1 Jun 23 | Gibson Neil W | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 16.1 | 5,000 | 80.50 k | 0 |
1 Jun 23 | Gibson Neil W | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 16.11 | 6,270 | 101.01 k | 0 |
1 Jun 23 | Gibson Neil W | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 0.97 | 16,800 | 16.30 k | 0 |
1 Jun 23 | Priti Hegde | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 16.02 | 24,968 | 399.99 k | 0 |
1 Jun 23 | Priti Hegde | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 5.21 | 12,100 | 63.04 k | 0 |
1 Jun 23 | Priti Hegde | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 0.97 | 16,800 | 16.30 k | 0 |
1 Jun 23 | Axel Hoos | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 5.21 | 12,100 | 63.04 k | 0 |